Research Centre, DR. G.M. Taori Central India Institute of Medical Sciences (CIIMS), Nagpur, India.
Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.
Epidemiol Health. 2021;43:e2021022. doi: 10.4178/epih.e2021022. Epub 2021 Apr 7.
India has a higher tuberculosis (TB) burden than any other country, accounting for an estimated one-fourth of the global burden. Drug-resistant tuberculosis (DR-TB) presents a major public health problem in India. Patients with DR-TB often require profound changes in their drug regimens, which are invariably linked to poor treatment adherence and sub-optimal treatment outcomes compared to drug-sensitive TB. The challenge of addressing DR-TB is critical for India, as India contributes over 27% of global DR-TB cases. In recent decades, India has been proactive in its battle against TB, even implementing a revised National Strategic Plan to eliminate TB by 2025. However, to achieve this ambitious goal, the country will need to take a multifaceted approach with respect to its management of DR-TB. Despite concerted efforts made by the National TB Elimination Program, India faces substantial challenges with regard to DR-TB care, especially in peripheral and resource-limited endemic zones. This article describes some of the major challenges associated with mitigating the growing DR-TB epidemic in India and their implications.
印度的结核病（TB）负担比任何其他国家都重，占全球负担的四分之一左右。耐多药结核病（DR-TB）在印度是一个主要的公共卫生问题。耐多药结核病患者通常需要对其药物治疗方案进行重大改变，与敏感结核病相比，他们的治疗依从性往往较差，治疗效果也不理想。解决耐多药结核病问题对印度来说至关重要，因为印度占全球耐多药结核病病例的 27%以上。近几十年来，印度在防治结核病方面一直很积极，甚至实施了修订后的国家战略计划，争取到 2025 年消灭结核病。然而，要实现这一雄心勃勃的目标，该国需要在耐多药结核病的管理方面采取多方面的方法。尽管国家结核病消除计划做出了协同努力，但印度在耐多药结核病护理方面仍面临重大挑战，特别是在周边和资源有限的流行地区。本文描述了与减轻印度日益严重的耐多药结核病流行相关的一些主要挑战及其影响。
